Carol Forsloff - Investigators at Albert Einstein College of Medicine have determined that resveratol might help improve insulin resistance and thereby be of benefit for Type 2 diabetes.
Resveratol is a chief ingredient in wine, which has also been used in some experiments in other medical conditions. In this case a study has used in supplement form.
The pilot study is called “Resveratrol Improves Glucose Metabolism in Older Adults with IGT”. The study involved group of older adults who were given the resveratrolsupplement Transmax, produced by nutraceutical company Biotivia LLC, on a daily basis over the course of four weeks. Results of the study of 10 individuals show that at moderate doses, Transmax resveratrol improved insulin resistance and lowered post-meal glucose levels in patients with IGT, a promising result for people with type 2 diabetes or at high risk for this condition.
The pilot study is called “Resveratrol Improves Glucose Metabolism in Older Adults with IGT”. The study involved group of older adults who were given the resveratrolsupplement Transmax, produced by nutraceutical company Biotivia LLC, on a daily basis over the course of four weeks. Results of the study of 10 individuals show that at moderate doses, Transmax resveratrol improved insulin resistance and lowered post-meal glucose levels in patients with IGT, a promising result for people with type 2 diabetes or at high risk for this condition.
The results of this study were considered sufficiently important for presentation to researchers assembled at the American Diabetes Association’s Annual Scientific Meeting this weekend. The resveratrol supplement used in the study, Transmax, is produced by Biotivia LLC of New York, a manufacturer of resveratrol-based health supplements. Another study recently completed at Northumbria University in the United Kingdom also used a Biotivia supplement to investigate brain blood flow and cognition after resveratrol consumption. That study found that resveratrol increased the volume of circulation to the cerebrum by as much as 200%. Resveratrol has been given more and more attention recently for a number of conditions that include providing benefits that include anti-inflammation, cardiovascular protection and improved physical and cognitive health.
The Albert Einstein trial appears to confirm resveratrol’s potential role as a beneficial modulator of insulin sensitivity, a key component of Type 2 diabetes.
“The results of this pilot study are preliminary and need to be confirmed in larger numbers of patients,” said Jill Crandall, M.D., Associate Professor of clinical medicine at Albert Einstein College of Medicine and lead investigator of the study. “However, we are encouraged by these findings and plan to conduct additional studies to further explore the potential utility of resveratrol in improving glucose metabolism.”
Prior to this study resveratrol had been tested in relation to diabetes only in animal subjects or on cell lines. Since those studies had promising results, this newest study on humans was anticipated to be positive.
“We find these results to be extremely encouraging but not at all surprising,” said Biotivia CEO and founder James Betz. “This human clinical trial confirms the insights gleaned from a substantial number of earlier in vitro and animal studies which have clearly elucidated the various biokinetic pathways and modalities via which resveratrol operates in animals. We have had good reason to believe for some time now that resveratrol has the potential to ameliorate or prevent many of the adverse health conditions associated with aging and various adverse contemporary environmental and life style factors.”
The study’s findings are bolstered by the results of several other resveratrol clinical trials to be presented at the ADA’s 70th Annual Meeting.
The Albert Einstein trial appears to confirm resveratrol’s potential role as a beneficial modulator of insulin sensitivity, a key component of Type 2 diabetes.
“The results of this pilot study are preliminary and need to be confirmed in larger numbers of patients,” said Jill Crandall, M.D., Associate Professor of clinical medicine at Albert Einstein College of Medicine and lead investigator of the study. “However, we are encouraged by these findings and plan to conduct additional studies to further explore the potential utility of resveratrol in improving glucose metabolism.”
Prior to this study resveratrol had been tested in relation to diabetes only in animal subjects or on cell lines. Since those studies had promising results, this newest study on humans was anticipated to be positive.
“We find these results to be extremely encouraging but not at all surprising,” said Biotivia CEO and founder James Betz. “This human clinical trial confirms the insights gleaned from a substantial number of earlier in vitro and animal studies which have clearly elucidated the various biokinetic pathways and modalities via which resveratrol operates in animals. We have had good reason to believe for some time now that resveratrol has the potential to ameliorate or prevent many of the adverse health conditions associated with aging and various adverse contemporary environmental and life style factors.”
The study’s findings are bolstered by the results of several other resveratrol clinical trials to be presented at the ADA’s 70th Annual Meeting.
No comments:
Post a Comment
Say something constructive. Negative remarks and name-calling are not allowed.